JEANATOPE
LOE Approachingalbumin iodinated i-125 serum
BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEANATOPE (Albumin Iodinated I-125 Serum) is a radioiodinated serum albumin diagnostic agent administered by injection. It is a legacy radiopharmaceutical used for imaging and diagnostic purposes, with a mechanism of action centered on radiolabeled protein distribution and localization.
LOE Approaching
This legacy diagnostic product is approaching loss of exclusivity with minimal linked career opportunities, indicating a contracting commercial footprint and reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job opportunities reflect this product's minimal commercial footprint and late lifecycle stage. Career roles focus on regulatory maintenance, compliance, and portfolio stewardship rather than brand growth or innovation.
Regulatory Affairs SpecialistProduct Manager (Legacy/Mature Portfolio)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.